2018 International Congress

Saturday, October 6, 2018

1:45pm-3:15pm

A new SPG4/SPAST mutation in an Italian family with hereditary spastic paraplegia and Alzheimer’s disease

A. Orlacchio, C. Montecchiani, R. Rumore, F. Gaudiello, M. Miele, C. Caltagirone, T. Kawarai (Rome, Italy)

Genetics (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

A novel homozygous splice site mutation in the KIF1C gene (SPAX2, SPG58) found in a consanguineous turkish family

E. Grauer, N. Pluta, P. Müller, D. Zeller, C. Ip, J. Volkmann, E. Kunstmann, T. Musacchio (Würzburg, Germany)

Rare Genetic and Metabolic Diseases  ·  Hall 3FG

1:45pm-3:15pm

A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID

D. Charvin, T. Di Paolo, E. Bezard, L. Gregoire, A. Takano, G. Duvey, E. Pioli, C. Halldin, R. Medori, F. Conquet (Plan-les-Ouates, Switzerland)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

A novel mutation in VRK1 associated with distal spinal muscular atrophy

L. Li, L. Wang, Z. Lu, X. Sun, X. Suo, J. Li, J. Peng, R. Peng (Chengdu, China)

Genetics (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone

S. Janhunen, J. Venäläinen, J. Kaskinoro, L. Saloranta, J. Tuunainen (Turku, Finland)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

A Patient-Centered Decision-Making Algorithm for Deep Brain Stimulation Surgery in Parkinson’s Disease

S. Joza, K. Yen, F. Ba, J. Miyasaki (Edmonton, AB, Canada)

Surgical Therapy: Parkinson's Disease  ·  Hall 3FG

1:45pm-3:15pm

A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale

S. Papapetropoulos, M. Lee, S. Boyer, M. Versavel (Cambridge, MA, USA)

Clinical Trials and Therapy in Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s disease: Study Design

T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Chicago, IL, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update

R. Holloway, D. Oakes, T. Simuni, K. Hodgeman, B. Greco, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, K. Biglan (Rochester, NY, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

A phase Ib trial studying the safety and tolerability of IRL790 in patients with Parkinson’s disease and levodopa-induced dyskinesia

P. Svenningsson, A. Johansson, D. Nyholm, P. Tsitsi, C. Sonesson, J. Tedroff (Stockholm, Sweden)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG